BACKGROUND: Current endoscopic pancreatic function test (ePFT) methods use either secretin or cholecystokinin (CCK) to measure pancreatic function. OBJECTIVE: To evaluate a novel ePFT protocol that includes both secretin and CCK stimulation and to assess which fluid parameters best discriminate patients with chronic pancreatitis (CP). DESIGN: Prospective, cross-sectional diagnostic study. SETTING: Single, tertiary-care institution. PATIENTS: Healthy volunteers and patients evaluated for CP were included. INTERVENTIONS: All patients underwent a combined secretin-CCK ePFT. Patients evaluated for CP also underwent EUS during the same endoscopic session. MAIN OUTCOME MEASUREMENTS: Duodenal fluid bicarbonate, lipase, and amylase concentrations were measured after CCK and secretin stimulation. Results were compared based on the presence of CP detected by EUS (≥5 features). RESULTS: Twenty healthy volunteers and 69 patients evaluated for CP completed the secretin and CCK ePFT. Patients with an EUS score of 5 or higher had significantly decreased peak bicarbonate concentrations (72 mmol) compared with patients with an EUS score lower than 5 (90 mmol) and healthy subjects (108 mmol) (P < .001). Peak concentrations of amylase and lipase and total fluid volume were not significantly different between patients with CP and controls. Receiver-operating characteristic analysis revealed that peak bicarbonate concentration had superior discrimination for CP (area under the curve [AUC] 0.738) compared with peak amylase (AUC 0.677) and peak lipase (AUC 0.627). The addition of enzyme concentration measurement did not improve discrimination compared with peak bicarbonate alone. LIMITATIONS: Secretin and cholecystokinin endoscopic pancreatic function test (SC ePFT) results were not compared with those of single hormone ePFTs. CONCLUSIONS: The addition of CCK infusion and enzyme concentration measurement to a standard secretin ePFT does not enhance the diagnosis of CP. Copyright Â
BACKGROUND: Current endoscopic pancreatic function test (ePFT) methods use either secretin or cholecystokinin (CCK) to measure pancreatic function. OBJECTIVE: To evaluate a novel ePFT protocol that includes both secretin and CCK stimulation and to assess which fluid parameters best discriminate patients with chronic pancreatitis (CP). DESIGN: Prospective, cross-sectional diagnostic study. SETTING: Single, tertiary-care institution. PATIENTS: Healthy volunteers and patients evaluated for CP were included. INTERVENTIONS: All patients underwent a combined secretin-CCK ePFT. Patients evaluated for CP also underwent EUS during the same endoscopic session. MAIN OUTCOME MEASUREMENTS: Duodenal fluid bicarbonate, lipase, and amylase concentrations were measured after CCK and secretin stimulation. Results were compared based on the presence of CP detected by EUS (≥5 features). RESULTS: Twenty healthy volunteers and 69 patients evaluated for CP completed the secretin and CCK ePFT. Patients with an EUS score of 5 or higher had significantly decreased peak bicarbonate concentrations (72 mmol) compared with patients with an EUS score lower than 5 (90 mmol) and healthy subjects (108 mmol) (P < .001). Peak concentrations of amylase and lipase and total fluid volume were not significantly different between patients with CP and controls. Receiver-operating characteristic analysis revealed that peak bicarbonate concentration had superior discrimination for CP (area under the curve [AUC] 0.738) compared with peak amylase (AUC 0.677) and peak lipase (AUC 0.627). The addition of enzyme concentration measurement did not improve discrimination compared with peak bicarbonate alone. LIMITATIONS: Secretin and cholecystokinin endoscopic pancreatic function test (SC ePFT) results were not compared with those of single hormone ePFTs. CONCLUSIONS: The addition of CCK infusion and enzyme concentration measurement to a standard secretin ePFT does not enhance the diagnosis of CP. Copyright Â
Authors: Tyler Stevens; John A Dumot; Gregory Zuccaro; John J Vargo; Mansour A Parsi; Rocio Lopez; H Lester Kirchner; Edward Purich; Darwin L Conwell Journal: Clin Gastroenterol Hepatol Date: 2008-09-17 Impact factor: 11.382
Authors: Darwin L Conwell; Gregory Zuccaro; J Brad Morrow; Frederick Van Lente; Cathy O'Laughlin; John J Vargo; John A Dumot Journal: Pancreas Date: 2002-11 Impact factor: 3.327
Authors: Tyler Stevens; Darwin L Conwell; Gregory Zuccaro; Frederick Van Lente; Edward Purich; Farah Khandwala; Seymour Fein Journal: Am J Gastroenterol Date: 2006-02 Impact factor: 10.864
Authors: Darwin L Conwell; Gregory Zuccaro; John J Vargo; Patricia A Trolli; Frederick Vanlente; Nancy Obuchowski; John A Dumot; Cathy O'laughlin Journal: Gastrointest Endosc Date: 2003-01 Impact factor: 9.427
Authors: Phil A Hart; Mark Topazian; Massimo Raimondo; Zobeida Cruz-Monserrate; William E Fisher; Gregory B Lesinski; Hanno Steen; Darwin L Conwell Journal: Am J Gastroenterol Date: 2016-08-02 Impact factor: 10.864